Document ID: chunk:federal_register_of_legislation:F2024C00658:reg:9:p6
Version: federal_register_of_legislation:F2024C00658
Segment Type: reg
Provision Reference: reg 9 (pt 6/7)
Character Range: 22305–25670

within the 4 weeks before clinical onset:
(a)          a non-penetrating injury, involving extension, rotation, hyperflexion or compression of the neck;
(b)          an injury resulting in fracture or dislocation of the cervical spine;
(c)          a penetrating injury to the neck or the base of the skull;
(d)          foreign body penetration or blunt injury of an artery within the head, neck or chest;
(59)      for brain ischaemia only, inhaling chronically polluted air for at least 1000 hours, within the 5 years before clinical onset;
Note: chronically polluted air is defined in the Schedule 1 – Dictionary.
(60)      for intracerebral haemorrhage only, undergoing anticoagulant therapy within the 30 days before clinical onset;
Note: anticoagulant therapy is defined in the Schedule 1 – Dictionary.
(61)      for intracerebral haemorrhage only, taking one of the following antiplatelet drugs on at least 3 days per week for a continuous period of at least 4 weeks before clinical onset, where the last dose was taken no more than 30 days before clinical onset:
(a)          aspirin;
(b)          clopidogrel;
(c)          prasugrel; or
(d)          ticagrelor;
(62)      for intracerebral haemorrhage only, undergoing thrombolytic (fibrinolytic) therapy within the 7 days before clinical onset;
Note: thrombolytic (fibrinolytic) therapy is defined in the Schedule 1 - Dictionary.
(63)      for intracerebral haemorrhage only, having one of the following disorders at the time of clinical onset:
(a)          aplastic anaemia;
(b)          idiopathic thrombocytopaenic purpura or immune thrombocytopaenia;
(c)          disseminated intravascular coagulation;
(d)          essential thrombocythaemia;
(e)          Hodgkin lymphoma;
(f)           inherited or acquired coagulation protein disorder, including haemophilia;
(g)          leukaemia;
(h)          myeloma;
(i)            non-Hodgkin lymphoma;
(j)            post-transfusion purpura;
(k)          qualitative platelet defects associated with coagulation defect;
(l)            thrombocytopaenia; or
(m)        vitamin K deficiency;
(64)      for intracerebral haemorrhage only, bleeding of one of the following intracerebral space occupying lesions at the time of the clinical onset:
            (a)          abscess;
            (b)          cyst;
            (c)          neoplasm; or
            (d)          tuberculoma;
(65)      for cerebral ischaemia only, having compression of the carotid, vertebral, basilar or cerebral artery at the time of clinical onset;
Note: Examples of a mass or structure that can cause compression include osteophytes associated with cervical spondylosis (especially with rotation of the neck beyond 45 degrees), an abscess, haematoma or neoplasm in the neck.
(66)      for intracerebral haemorrhage only, bleeding from a cerebral aneurysm or a cerebral vascular malformation at the time of clinical onset;
(67)      taking an antipsychotic drug on more days than not for at least one week, within the 6 months before clinical onset;
(68)      taking tibolone for a continuous period of at least 21 days within the 2 months before clinical onset;
(69)      taking a systemic vascular endothelial growth factor (VEGF) inhibitor or monthly intra-vitreous injections of a VEGF inhibitor within the 4 months before clinical onset;
Note: Vascular endothelial growth